Alto Neuroscience (NYSE:ANRO) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Alto Neuroscience (NYSE:ANRO) from a sell rating to a hold rating in a research note released on Saturday morning.

A number of other brokerages have also recently issued reports on ANRO. Robert W. Baird reduced their price objective on shares of Alto Neuroscience from $41.00 to $38.00 and set an “outperform” rating for the company in a report on Thursday, April 2nd. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Alto Neuroscience in a report on Thursday, April 2nd. Chardan Capital reiterated a “buy” rating and set a $30.00 price objective on shares of Alto Neuroscience in a report on Wednesday, April 22nd. Bank of America assumed coverage on shares of Alto Neuroscience in a report on Tuesday, May 5th. They set a “buy” rating and a $35.00 price objective for the company. Finally, BTIG Research lifted their price objective on shares of Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Alto Neuroscience has an average rating of “Moderate Buy” and a consensus target price of $35.13.

Alto Neuroscience Trading Up 0.8%

NYSE:ANRO opened at $24.26 on Friday. The stock has a market capitalization of $775.08 million, a price-to-earnings ratio of -11.13 and a beta of 1.62. The firm has a fifty day simple moving average of $22.78 and a two-hundred day simple moving average of $18.00. Alto Neuroscience has a 12 month low of $2.15 and a 12 month high of $28.44. The company has a current ratio of 15.69, a quick ratio of 15.69 and a debt-to-equity ratio of 0.12.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings data on Monday, March 16th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.11. Analysts expect that Alto Neuroscience will post -2.47 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC purchased a new position in Alto Neuroscience during the first quarter worth about $52,000. Torren Management LLC purchased a new position in Alto Neuroscience during the fourth quarter worth about $62,000. Invesco Ltd. purchased a new position in Alto Neuroscience during the first quarter worth about $67,000. Vanguard Personalized Indexing Management LLC boosted its holdings in Alto Neuroscience by 13.7% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock worth $69,000 after purchasing an additional 2,055 shares during the last quarter. Finally, Bridgeway Capital Management LLC raised its position in Alto Neuroscience by 85.9% in the second quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock worth $119,000 after acquiring an additional 25,000 shares during the period.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.